Table 2.

Association between platelet count and risk of lung cancer using multiple instrumental variable analysis

Overall NSCLCAdenocarcinomaSCCSCLC
SNPOR (95% CI)POR (95% CI)POR (95% CI)POR (95% CI)P
IVW1.62 (1.15–2.27)0.0051.51 (0.92–2.48)0.111.59 (0.86–2.92)0.143.00 (1.27–7.06)0.01
Penalized IVW1.62 (1.15–2.27)0.0051.51 (0.92–2.48)0.111.59 (0.86–2.92)0.143.00 (1.27–7.06)0.01
Robust IVW1.63 (1.26–2.11)<0.0011.51 (0.90–2.53)0.121.54 (0.93–2.56)0.093.30 (1.52–7.15)0.003
MR-Egger3.25 (1.16–9.11)0.036.06 (1.45–25.27)0.011.75 (0.22–13.84)0.593.29 (0.24–45.11)0.37
Penalized MR-Egger3.25 (1.16–9.11)0.036.06 (1.45–25.27)0.011.75 (0.22–13.84)0.593.29 (0.24–45.11)0.37
Robust MR-Egger3.23 (1.80–5.78)<0.0015.88 (2.74–12.61)<0.0011.70 (0.48–6.08)0.413.56 (1.25–10.14)0.02
  • NOTE: OR of platelet count on lung cancer risk per 100 × 109/L increment of platelet count.